Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3841 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Study rejects toxin as key to MRSA

Many researchers believed that the toxin Panton-Valentine leukocidin (PVL) was the cause of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) as it could be found in all CA-MRSA strains. But

Cobalis says patient input completed in trial

The trials are designed to test the safety and efficacy of pre-seasonal treatment with PreHistin on moderate to moderately severe seasonal ragweed allergy patients. The phase III trials

PTC initiates dosing study of cancer drug

PTC299 is an orally bioavailable drug designed to modulate RNA-mediated protein expression to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. PTC has recently completed

Novartis inflammatory drug cleared for EU

All 26 EU member states have agreed to issue national approval to Prexige. Novartis also reported that the drug has been authorized in Canada. Initial approval for Prexige

FDA OKs Cadila cholesterol treatment

The drug, a lipid-lowering agent which helps to prevent a stroke or heart attack, falls in the cardiovascular segment of the market, the company noted. Cadila said it

Novelos initiates lung cancer trial

This phase III trial will specifically study patients with advanced non-small cell lung cancer (NSCLC). It will evaluate NOV-002 in combination with paclitaxel and carboplatin versus paclitaxel and

Generex to conduct first human H5N1 trial

Antigen Express, a wholly owned subsidiary of Generex, designed the vaccine using its proprietary platform technology and has been conducting preclinical studies since 2004. Generex commented that the